TMCnet News
Advanced Cell Technology's Chief Scientific Officer Dr. Robert Lanza Named One of TIME Magazine's 100 Most Influential People in the WorldMARLBOROUGH, Mass. --(Business Wire)-- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the company's Chief Scientific Officer, Robert Lanza, MD, has been selected for the 2014 TIME 100 annual list of the hundred most influential people in the world. The TIME 100 issue, containing the full list hits newsstands on Friday, April 25. A gala honoring this years' TIME 100 will be held on Tuesday, April 29, 2014 at Jazz at Lincoln Center in New York City. The event brings together the world's leading figures in politics, technology, science, philanthropy, media, business and entertainment and attracts worldwide media coverage. Last year's gala featured a performance by Christina Aguilera and remarks by Vice President Joe Biden; the previous year's keynote speaker was Secretary of State Hillary Clinton, with performaces by Rihanna and Stephen Colbert. Past guests have included President Bill Clinton, Justin Timberlake, Oprah Winfrey, Carlos Slim, Amy Poehler, Jeremy Lin, Gabrielle Giffords, Steven Spielberg and Lena Dunham as well as activists and thinkers who are making a difference in the world, whether fighting for human rights or seeking a cure for cancer. About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc., (ACT) is a Marlborough, Mass.-based biotechnology company focused on the development and commercialization of human embryonic stem cell (hESC) and adult stem cell technology. The company's most advanced products are in clinical trials for the treatment of dry age-related macular degeneration and Stargardt's macular degeneration. These cell therapies are also clinical trial candidates for the treatment of myopic macular degeneration. ACT's preclinical programs involve cell therapies for the treatment of other ocular disorders and for diseases outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders. The company's intellectual property portfolio includes pluripotent stem cell platforms - hESC and induced pluripotent stem cell (iPSC) - and other cell therapy research programs. For more information, visit www.advancedcell.com or connect with the Company on Facebook, Twitter, LinkedIn, Google (News - Alert)+ and YouTube.
|
